M C Chabot - JoVE Visualize

Showing results (11-20 of 14) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 14 results.

Journal of Spinal Disorders|January 23, 1998

Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion modelJ S Fischgrund, S B James, M C Chabot, et al.

The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995

Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthmaM C Chabot-Fletcher, D C Underwood, J J Breton, et al.

The Biochemical Journal|March 24, 2000

Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cellsR C Gardner, S J Assinder, G Christie, et al.

Journal of Medicinal Chemistry|September 27, 1996

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potencyJ C Boehm, J M Smietana, M E Sorenson, et al.

Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 14 results.

Journal of Spinal Disorders|January 23, 1998

Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion modelJ S Fischgrund, S B James, M C Chabot, et al.

The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995

Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthmaM C Chabot-Fletcher, D C Underwood, J J Breton, et al.

The Biochemical Journal|March 24, 2000

Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cellsR C Gardner, S J Assinder, G Christie, et al.

Journal of Medicinal Chemistry|September 27, 1996

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potencyJ C Boehm, J M Smietana, M E Sorenson, et al.

Pageof 2